I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Solid Tumours

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Sep 15 / Roche and Genentech
Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry
The poster describes NGS in routine care in most common cancer types using the global WAYFIND-R registry database.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 14 / Roche and Genentech
Phase I Study of SOF10 Plus Atezolizumab in Patients with Advanced/Recurrent Solid Tumours
This was a Phase I, multicentre, open-label, dose-escalation study (jRCT2031200407) to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumour activity of SOF10 (100-1800 mg) + atezolizumab (1200 mg) administered intravenously in patients with advanced/recurrent solid tumours.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 14 / Roche
WAYFIND-R: A Global, Real-World Precision Oncology Registry – Socioeconomic Features
WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS).

Sign up or login to unlock the full suite of MEDICALLY features

Nov 3 / Roche and Genentech
A Phase I study of a tumor-targeted fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
Fibroblast activation protein (FAP)-CD40 is a FAP-targeted CD40 agonist bispecific antibody that was developed to overcome the systemic toxicities and narrow therapeutic index of conventional anti-CD40 therapies. This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of FAP-CD40 in adults with solid tumors.

Ask a question or share feedback